Silence Therapeutics plc

NASDAQ:SLN

Biotechnology

Healthcare
$19.82 +2.81%

+$0.19 today

Market cap
$936.18M
Beta
1.48
P/E (TTM)
-3.9
EPS (TTM)
-$1.80
52W Low $4.19High $8.40

Volume 1.47M

Average 0.31M

SLN Income Before Tax

Profit after all operating and non-operating items but before income tax.

Silence Therapeutics plcNASDAQ: SLN

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$14.93M, compared with -$36.91M a year earlier. Trailing-twelve-month income before tax was -$85.16M.

Context

  • Income before tax amounted to 15849.9% of revenue in FY2025, up 15747.1 pp from a year earlier.
  • Income before tax grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$14.93M or moves back toward the trailing-twelve-month quarterly average of -$21.29M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$14.93M-26.9% QoQ
Last fiscal yearDec 2025
-$88.6M-99.3% YoY
LTMMar 2026
-$85.16M— YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+59.5%——
1 year-99.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

Mixed currencies · from the income statement

Latest · FY2025
(88.6M) USD
Year-over-year change
—

Income Before Tax vs competitors

How SLN compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Income before tax amounts to 9241.5% of revenue for SLN, versus a peer median of 173.5%.
SLN Competitors
Income Before Tax for SLN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$24.47M USD+114.9%—1.1%
PRQRProQR Therapeutics N.V.LTM Mar 2026-€45.61M EUR-50.1%—339.3%
BNTCBenitec Biopharma Inc.LTM Mar 2026-$48.88M USD-44.5%——
RNAAtrium Therapeutics, Inc.FY2025-$76.83M USD——412.6%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-$78.67M USD-14.7%—173.5%
SLNSilence Therapeutics plcLTM Mar 2026-$85.16M USD——9241.5%
WVEWave Life Sciences Ltd.LTM Mar 2026-$183.59M USD-63.4%—255.7%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-$543.8M USD-110.2%—56.7%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026-$723.91M USD-1504.8%—160.6%
ADRXADARx Pharmaceuticals, Inc.—— ———
Peer median (excluding SLN) —-50.1%—173.5%

Competitors are the stored peer set for SLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · GBP
FY2022
Dec 2022 · GBP
FY2023
Dec 2023 · GBP
FY2024
Dec 2024 · GBP
FY2025
Dec 2025 · USD
Revenue12.42M17.65M25.38M43.26M559K
Cost of Revenue7.46M10.97M10.32M11.81M215K
Gross Profit4.96M6.68M15.06M31.45M344K
Gross Margin39.9%37.8%59.3%72.7%61.5%
Research & Development30.77M35.5M44.03M67.88M67.75M
Selling, General & Admin20.01M20.94M20.64M26.88M22.34M
Operating Expenses50.77M56.44M64.66M94.77M90.1M
Depreciation & Amortization427K485.86K498K593K555K
EBITDA(45.42M)(39.94M)(49.78M)(48.99M)(88.05M)
EBITDA Margin-365.9%-226.2%-196.2%-113.2%-15750.6%
Operating Income(45.81M)(49.76M)(49.6M)(63.32M)(89.75M)
Operating Margin-369.0%-281.9%-195.5%-146.4%-16056.0%
Interest Income10K226K1.45M4.47M3.48M
Interest Expense8K47K34K00
Other Income / Expenses(42K)9.29M(706K)18.86M1.15M
Income Before Tax(45.86M)(40.47M)(50.31M)(44.46M)(88.6M)
Pre-Tax Margin-369.4%-229.3%-198.3%-102.8%-15849.9%
Income Tax Expense(6.45M)560.85K(7.04M)845K11K
Net Income(39.41M)(41.03M)(43.27M)(45.31M)(88.61M)
Net Margin-317.4%-232.4%-170.5%-104.7%-15851.9%
EPS (Basic)(1.35)(3.78)(3.48)(2.37)(1.89)
EPS (Diluted)(1.35)(3.78)(3.48)(2.37)(1.89)
Weighted Avg Shares29.65M10.73M12.36M15.42M47.23M
Weighted Avg Shares (Diluted)29.65M10.73M12.36M15.42M47.23M

Silence Therapeutics plc

NASDAQ:SLN

Intrinsic Alpha fair value

Locked

Current Price

$19.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.